Drug Discovery & DDS– category –
-
Agentic and Generative AI to Revolutionize Cardiovascular Drug Discovery
American Heart Association Journals USA Overview Large Language Models (LLMs) and agentic AI are poised to fundamentally transform cardiovascular disease (CVD) drug development by enhancing target understanding, accelerating novel compou... -
Kymera Therapeutics’ Oral STAT6 Degrader KT-621 Shows Positive Phase 1b Atopic Dermatitis Data, Potential Injectable Alternative
TradingView Global Overview Kymera Therapeutics' lead candidate, KT-621 (an oral STAT6 degrader leveraging targeted protein degradation), demonstrated positive Phase 1b data in atopic dermatitis. Presented at the American Academy of Derm... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
FDA Grants Accelerated Approval to Regeneron’s Bispecific Antibody Linvoseltamab (LYNOZYFIC) for Multiple Myeloma
International Myeloma Foundation USA Overview The International Myeloma Foundation reported that LYNOZYFIC (linvoseltamab-gcpt), a BCMA-CD3 bispecific antibody immunotherapy, received accelerated FDA approval in July 2025. This drug targ... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
GLP-1 Review Finds Strongest Signals for GI Adverse Events, Hints at Reduced Infection/Respiratory Risk
GI and Hepatology News USA Overview A systematic review and meta-analysis published in JAMA Network Open found that GLP-1 receptor agonists (GLP-1 RAs) consistently increase gastrointestinal side effects like nausea, vomiting, and diarrh... -
bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges
bioRxiv USA Overview A bioRxiv preprint introduces a novel 'post-loading' strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to admi... -
Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy
Imperial College London UK Overview Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-spe... -
Bambusa Therapeutics’ Bispecific Antibody BBT001 Achieves Rapid, Durable Itch Relief and AD Improvement in Phase 1 Atopic Dermatitis Trial
Dermatology Times USA Overview Preliminary Phase 1 clinical data for Bambusa Therapeutics' bispecific antibody BBT001 shows rapid and sustained improvement in disease severity and pruritus in moderate-to-severe atopic dermatitis (AD) pat...
